KR101979045B1 - 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 - Google Patents

당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 Download PDF

Info

Publication number
KR101979045B1
KR101979045B1 KR1020147010631A KR20147010631A KR101979045B1 KR 101979045 B1 KR101979045 B1 KR 101979045B1 KR 1020147010631 A KR1020147010631 A KR 1020147010631A KR 20147010631 A KR20147010631 A KR 20147010631A KR 101979045 B1 KR101979045 B1 KR 101979045B1
Authority
KR
South Korea
Prior art keywords
sugar chain
leu
polypeptide
group
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147010631A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095051A (ko
Inventor
이즈미 사카모토
카즈히로 후카에
카츠나리 테즈카
케이스케 타즈루
마사토시 마에다
야스히로 카지하라
타카시 츠지
Original Assignee
가부시키가이샤 도우사 고가쿠 겐큐쇼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 도우사 고가쿠 겐큐쇼 filed Critical 가부시키가이샤 도우사 고가쿠 겐큐쇼
Publication of KR20140095051A publication Critical patent/KR20140095051A/ko
Application granted granted Critical
Publication of KR101979045B1 publication Critical patent/KR101979045B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147010631A 2011-10-01 2012-09-28 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 Expired - Fee Related KR101979045B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011218793 2011-10-01
JPJP-P-2011-218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
KR20140095051A KR20140095051A (ko) 2014-07-31
KR101979045B1 true KR101979045B1 (ko) 2019-05-15

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010631A Expired - Fee Related KR101979045B1 (ko) 2011-10-01 2012-09-28 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물

Country Status (16)

Country Link
US (1) US10358470B2 (enExample)
EP (1) EP2762489B1 (enExample)
JP (1) JP6153470B2 (enExample)
KR (1) KR101979045B1 (enExample)
CN (2) CN104080803B (enExample)
AU (1) AU2012317325B2 (enExample)
BR (1) BR112014007766B1 (enExample)
CA (1) CA2850469C (enExample)
DK (1) DK2762489T3 (enExample)
IN (1) IN2014CN02982A (enExample)
MY (1) MY168902A (enExample)
PH (1) PH12014500694B1 (enExample)
RU (1) RU2636456C2 (enExample)
SG (2) SG11201401071YA (enExample)
TW (1) TWI633115B (enExample)
WO (1) WO2013047846A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
ES2218806T3 (es) 1997-01-16 2004-11-16 Neose Technologies, Inc. Sialilacion practica in vitro de glicoproteinas recombinantes.
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
BR9910023A (pt) * 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
DE60037978T2 (de) * 1999-12-08 2008-05-21 Amgen Inc., Thousand Oaks Interferon ähnliche moleküle, und deren verwendungen
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2001273385B2 (en) 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
CA2441095A1 (en) 2001-03-15 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon beta with reduced immunogenicity
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
EP2305312B1 (en) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
MXPA04008798A (es) 2002-03-12 2004-11-26 Maxygen Aps Moleculas semejantes a interferon beta para el tratamiento de evento cerebrovascular.
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
PL377612A1 (pl) * 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
AU2003292792A1 (en) 2002-12-26 2004-07-22 Kajihara, Yasuhiro Sugar-chain asparagine derivatives and processes for the preparation thereof
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
JP2007526317A (ja) 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド インターフェロン−ベータ・ポリマー結合体
EP1789074A4 (en) 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
KR100781666B1 (ko) 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
TWI423821B (zh) 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1 peptide
AU2008283317B2 (en) 2007-07-31 2012-08-02 Glytech, Inc. Method for producing peptide
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
JP5604297B2 (ja) 2008-06-17 2014-10-08 株式会社糖鎖工学研究所 糖鎖付加ｇｌｐ−１ペプチド
KR20110067097A (ko) * 2008-08-19 2011-06-21 오츠카 가가쿠 가부시키가이샤 당단백질의 제조방법 및 스크리닝 방법
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
SG193377A1 (en) 2011-03-10 2013-10-30 Glytech Inc Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
ES2774284T3 (es) 2011-06-29 2020-07-20 Kyowa Kirin Co Ltd Método para purificar antitrombina
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Also Published As

Publication number Publication date
EP2762489A9 (en) 2015-02-11
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
CN104080803A (zh) 2014-10-01
US10358470B2 (en) 2019-07-23
RU2014116550A (ru) 2015-10-27
RU2636456C2 (ru) 2017-11-23
MY168902A (en) 2018-12-04
BR112014007766A2 (pt) 2017-04-04
DK2762489T3 (en) 2018-07-02
CN104080803B (zh) 2020-08-04
JP6153470B2 (ja) 2017-06-28
CN109134642A (zh) 2019-01-04
AU2012317325B2 (en) 2016-10-06
EP2762489B1 (en) 2018-03-28
EP2762489A1 (en) 2014-08-06
US20140369964A1 (en) 2014-12-18
EP2762489A4 (en) 2015-05-06
IN2014CN02982A (enExample) 2015-07-03
SG11201401071YA (en) 2014-08-28
CA2850469A1 (en) 2013-04-04
TW201321404A (zh) 2013-06-01
KR20140095051A (ko) 2014-07-31
PH12014500694B1 (en) 2020-01-31
BR112014007766B1 (pt) 2022-05-10
WO2013047846A1 (ja) 2013-04-04
TWI633115B (zh) 2018-08-21
JPWO2013047846A1 (ja) 2015-03-30
PH12014500694A1 (en) 2014-05-12
AU2012317325A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
JP5517620B2 (ja) ペプチドの製造方法
EP2495255A1 (en) Glycosylated form of antigenic glp-1 analogue
CN102083854A (zh) 附加了糖链的glp-1肽
JP5925760B2 (ja) シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド
KR101979045B1 (ko) 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
WO2011007747A1 (ja) 糖鎖付加ａｉｌｉｍ細胞外ドメイン及びその製造方法
EP2982686B1 (en) Polypeptide having sialylated sugar chains attached thereto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240510

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240510